HRP20170445T1 - Poboljšani rekonstituirani pripravak surfaktanta koji sadrži analoge surfaktant-proteina b (sp-b) i surfaktant-proteina c (sp-c) - Google Patents
Poboljšani rekonstituirani pripravak surfaktanta koji sadrži analoge surfaktant-proteina b (sp-b) i surfaktant-proteina c (sp-c) Download PDFInfo
- Publication number
- HRP20170445T1 HRP20170445T1 HRP20170445TT HRP20170445T HRP20170445T1 HR P20170445 T1 HRP20170445 T1 HR P20170445T1 HR P20170445T T HRP20170445T T HR P20170445TT HR P20170445 T HRP20170445 T HR P20170445T HR P20170445 T1 HRP20170445 T1 HR P20170445T1
- Authority
- HR
- Croatia
- Prior art keywords
- surfactant
- reconstituted surfactant
- reconstituted
- protein
- seq
- Prior art date
Links
- 239000004094 surface-active agent Substances 0.000 title claims 19
- 239000000203 mixture Substances 0.000 title claims 3
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 title 1
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 title 1
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 title 1
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 6
- PAZGBAOHGQRCBP-ZCXUNETKSA-N 1-Palmitoyl-2-oleoylglycero-3-phosphoglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC PAZGBAOHGQRCBP-ZCXUNETKSA-N 0.000 claims 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 claims 3
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims 3
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003904 phospholipids Chemical class 0.000 claims 3
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims 2
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- NRBLBEWYHRQCIG-AKVLDSKYSA-N [(2R)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(Z)-octadec-9-enoxy]propyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OCCCCCCCC\C=C/CCCCCCCC NRBLBEWYHRQCIG-AKVLDSKYSA-N 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 239000007900 aqueous suspension Substances 0.000 claims 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 206010036590 Premature baby Diseases 0.000 claims 1
- 159000000021 acetate salts Chemical group 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 150000002019 disulfides Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0082—Lung surfactant, artificial mucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Cosmetics (AREA)
- General Preparation And Processing Of Foods (AREA)
Claims (15)
1. Rekonstituirani pripravak surfaktanta koji sadrži sljedeće:
a) od 1.2 do 1.8% po masi polipeptidnog analoga prirodnog surfaktant-proteina SP-C koji se sastoji od sekvencije prikazane formulom IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL (SEQ. ID NO:1);
b) od 0.1 do 0.5% po masi polipeptidnog analoga prirodnog surfaktant-proteina SP-B koji se sastoji od sekvencije prikazane formulom CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS (SEQ. ID NO:2);
c) mononezasićeni i zasićeni fosfolipid čiji je omjer mase u rasponu od 45: 55 do 55:45, gdje je rečeni mononezasićeni fosfolipid odabran iz skupine koja se sastoji od palmitoiloleoilfosfatidilkolina (POPC) i palmitoiloleoilfosfatidilglicerola (POPG) te gdje je rečeni zasićeni fosfolipid odabran iz skupine koja se sastoji od dipalmitoilfosfatidilkolina (DPPC) i dipalmitoilfosfatidilglicerola (DPPG);
sve su količine izračunate relativno prema ukupnoj masi rekonstituiranog surfaktanta.
2. Rekonstituirani surfaktant prema patentnom zahtjevu 1, naznačeno time da sadrži sljedeće:
a) oko 1.5% po masi polipeptidnog analoga prirodnog surfaktant-proteina SP-C koji se sastoji od sekvencije prikazane formulom IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL (SEQ. ID NO:1);
b) oko 0.2% po masi polipeptidnog analoga prirodnog surfaktant-proteina SP-B koji se sastoji od sekvencije prikazane formulom CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS (SEQ. ID NO:2);
c) 1,2-dipalmitoil-sn-glicero-3-fosfokolin (DPPC) i 1-palmitoil-2-oleil-sn-glicero-3-fosfoglicerol (POPG) u omjeru masa od oko 50:50;
sve su količine izračunate relativno prema ukupnoj masi rekonstituiranog surfaktanta.
3. Rekonstituirani surfaktant prema patentnom zahtjevu 2, naznačeno time da sadrži sljedeće:
a) oko 1.5% po masi polipeptidnog analoga prirodnog surfaktant-proteina SP-C koji se sastoji od sekvencije prikazane formulom IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL (SEQ ID:NO.1);
b) oko 0.2% po masi polipeptidnog analoga prirodnog surfaktant-proteina SP-B koji se sastoji od sekvencije prikazane formulom CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS (SEQ ID:NO.2);
c) oko 49.15% po masi 1,2-dipalmitoil-sn-glicero-3-fosfokolina (DPPC); te
d) oko 49.15% po masi 1-palmitoil-2-oleil-sn-glicero-3-fosfoglicerola (POPG);
sve su količine izračunate na ukupnoj masi rekonstituiranog surfaktanta.
4. Rekonstituirani surfaktant prema bilo kojem od patentnih zahtjeva 1 do 3, naznačeno time da je polipeptid SEQ ID:NO.2 u obliku disulfidom povezane molekule s intramolekulskom disulfidnom vezom između dvaju cisteinskih ostataka na položajima 1 i 33 i/ili između dvaju cisteinskih ostataka na položajima 4 i 27.
5. Rekonstituirani surfaktant prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time da je POPG u obliku farmaceutski prihvatljive soli.
6. Rekonstituirani surfaktant prema patentnom zahtjevu 5, naznačeno time da sol jest natrijeva sol.
7. Rekonstituirani surfaktant prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time da je svaki od rečenih polipeptida prisutan u obliku farmaceutski prihvatljive soli.
8. Rekonstituirani surfaktant prema patentnom zahtjevu 7, naznačeno time da sol jest acetatna sol.
9. Farmaceutska formulacija koja sadrži rekonstituirani surfaktant prema bilo kojem od patentnih zahtjeva 1 do 8, naznačeno time da je rečena formulacija u obliku otopine, disperzije, suspenzije ili suhog praška, a može biti u kombinaciji s jednim ili više farmaceutski prihvatljivih nosača.
10. Farmaceutska formulacija prema patentnom zahtjevu 9, naznačeno time da je rečena formulacija u obliku vodene suspenzije.
11. Farmaceutska formulacija prema patentnom zahtjevu 10, naznačeno time da je koncentracija rekonstituiranog surfaktanta između 0.1 i 160 mg/ml u vodenoj suspenziji.
12. Farmaceutski komplet koji sadrži sljedeće:
a) rekonstituirani surfaktant prema bilo kojem od patentnih zahtjeva 1 do 8 u obliku praška u prvoj jedinici oblika doze;
b) farmaceutski prihvatljiv nosač u drugoj jedinici oblika doze; te
c) spremnik koji sadržava rečeni prvi i drugi oblik doze.
13. Rekonstituirani surfaktant prema bilo kojem od patentnih zahtjeva 1 do 8, naznačeno time da je za upotrebu kao lijek.
14. Rekonstituirani surfaktant prema bilo kojem od patentnih zahtjeva 1 do 8, naznačeno time da je za upotrebu za liječenje ili profilaksu respiratornog distres sindroma (RDS) kod prerano rođenih beba ili za liječenje ili profilaksu ostalih bolesti povezanih s nedostatkom ili disfunkcijom surfaktanta.
15. Rekonstituirani surfaktant za upotrebu prema patentnom zahtjevu 14, naznačeno time da bolest uključuje RDS kod odraslih (ARDS), sindrom aspiracije mekonija (MAS) i bronhopulmonarnu displaziju (BPD).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09162052 | 2009-06-05 | ||
| PCT/EP2010/003293 WO2010139442A1 (en) | 2009-06-05 | 2010-05-31 | Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
| EP10724708.2A EP2438086B1 (en) | 2009-06-05 | 2010-05-31 | Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170445T1 true HRP20170445T1 (hr) | 2017-05-19 |
Family
ID=41055357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170445TT HRP20170445T1 (hr) | 2009-06-05 | 2017-03-21 | Poboljšani rekonstituirani pripravak surfaktanta koji sadrži analoge surfaktant-proteina b (sp-b) i surfaktant-proteina c (sp-c) |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8399406B2 (hr) |
| EP (1) | EP2438086B1 (hr) |
| JP (1) | JP5666569B2 (hr) |
| KR (1) | KR101668137B1 (hr) |
| CN (1) | CN102459327B (hr) |
| AR (1) | AR076973A1 (hr) |
| AU (1) | AU2010256066B2 (hr) |
| BR (1) | BRPI1010120B1 (hr) |
| CA (1) | CA2764454C (hr) |
| CL (1) | CL2011003003A1 (hr) |
| CO (1) | CO6470858A2 (hr) |
| CY (1) | CY1118676T1 (hr) |
| DK (1) | DK2438086T3 (hr) |
| EA (1) | EA021163B1 (hr) |
| ES (1) | ES2621974T3 (hr) |
| GE (1) | GEP20135967B (hr) |
| HK (1) | HK1166332A1 (hr) |
| HR (1) | HRP20170445T1 (hr) |
| HU (1) | HUE034053T2 (hr) |
| IL (1) | IL216718A (hr) |
| JO (1) | JO3226B1 (hr) |
| LT (1) | LT2438086T (hr) |
| MA (1) | MA33374B1 (hr) |
| ME (1) | ME01279B (hr) |
| MX (1) | MX2011012951A (hr) |
| MY (1) | MY159464A (hr) |
| NZ (1) | NZ596848A (hr) |
| PE (1) | PE20120541A1 (hr) |
| PL (1) | PL2438086T3 (hr) |
| PT (1) | PT2438086T (hr) |
| SG (1) | SG176305A1 (hr) |
| SI (1) | SI2438086T1 (hr) |
| TN (1) | TN2011000558A1 (hr) |
| TW (1) | TWI457132B (hr) |
| UA (1) | UA103526C2 (hr) |
| WO (1) | WO2010139442A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8968786B2 (en) | 2007-06-22 | 2015-03-03 | Board Of Regents, The University Of Texas System | Formation of stable submicron peptide or protein particles by thin film freezing |
| CA2829629A1 (en) * | 2011-03-10 | 2012-09-13 | Board Of Regents, The University Of Texas System | Protein nanoparticle dispersions |
| EP2812018B1 (en) * | 2012-02-09 | 2018-12-05 | University Of Rochester | Novel sp-b&sp-c peptides, synthetic lung surfactants, and use thereof |
| ES2644317T3 (es) | 2012-11-21 | 2017-11-28 | Chiesi Farmaceutici S.P.A. | Tensioactivos pulmonares reconstituidos |
| CN104382942A (zh) * | 2014-11-05 | 2015-03-04 | 烟台东诚药业集团股份有限公司 | 一种猪肺表面活性物质混悬液制备新工艺 |
| EP3106090A1 (en) | 2015-06-15 | 2016-12-21 | CHIESI FARMACEUTICI S.p.A. | System for effective breath-synchronized delivery of medicament to the lungs |
| CN107666933A (zh) | 2015-04-22 | 2018-02-06 | 奇斯药制品公司 | 用于药物有效地呼吸同步递送到肺部的方法和系统 |
| US11311691B2 (en) | 2015-04-28 | 2022-04-26 | Chiesi Farmaceutici S.P.A | Device for facilitating the administration of a medicament to the lung by a catheter |
| EP3452041A4 (en) * | 2016-03-07 | 2020-11-11 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | COMPOSITIONS AND METHOD OF ADMINISTRATION OF PPAR AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS |
| CA3028551A1 (en) | 2016-07-28 | 2018-02-01 | Chiesi Farmaceutici S.P.A. | Method and system for delivery of an aerosolized medicament |
| KR102395835B1 (ko) | 2016-08-24 | 2022-05-10 | 키에시 파르마슈티시 엣스. 피. 에이. | 재구성된 폐 계면활성제 조성물을 포함하는 안정한 약제학적 제제 |
| BR112019008169A2 (pt) | 2016-10-26 | 2019-07-09 | Chiesi Farm Spa | dispositivo para facilitar o posicionamento de um cateter, sistema para entrega de um medicamento em aerossol por meio de um cateter, método para utilização de um dispositivo e kit |
| EP3558376B1 (en) | 2016-12-22 | 2021-10-20 | Chiesi Farmaceutici S.p.A. | A therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving bpd |
| TW201927286A (zh) | 2017-12-15 | 2019-07-16 | 義大利商凱西製藥公司 | 用於噴霧投藥之包含肺表面張力素的藥學調配物 |
| WO2019115771A1 (en) | 2017-12-15 | 2019-06-20 | Pari Pharma Gmbh | Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method |
| AU2019260526A1 (en) | 2018-04-23 | 2020-11-19 | Chiesi Farmaceutici S.P.A. | A therapeutic combination comprising a pulmonary surfactant and a steroid for the prophylaxis of BPD |
| EP3666316A1 (en) | 2018-12-14 | 2020-06-17 | PARI Pharma GmbH | Aerosol delivery device and method of operating the aerosol delivery device |
| EP3666315A1 (en) | 2018-12-14 | 2020-06-17 | PARI Pharma GmbH | Aerosol delivery device and method of operating the aerosol delivery device |
| EP3843105A1 (en) | 2019-12-23 | 2021-06-30 | PARI Pharma GmbH | Control device for aerosol nebulizer system |
| US20230257446A1 (en) | 2020-01-28 | 2023-08-17 | Chiesi Farmaceutici S.P.A. | Polypeptides having improved properties |
| EP4366691A1 (en) | 2021-07-05 | 2024-05-15 | Chiesi Farmaceutici S.p.A. | Process for the preparation of a pulmonary surfactant |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2372558A1 (en) | 1999-06-11 | 2000-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
| ITMI20021058A1 (it) * | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
| EP1481665A1 (en) * | 2003-05-30 | 2004-12-01 | CHIESI FARMACEUTICI S.p.A. | Novel lipid mixtures for synthetic surfactants |
| KR101243867B1 (ko) * | 2005-05-11 | 2013-03-20 | 야마사 쇼유 가부시키가이샤 | 폐서팩턴트 단백질의 안정화법 |
| WO2008011559A2 (en) | 2006-07-20 | 2008-01-24 | University Of Rochester | Synthetic lung surfactant and use thereof |
| DK2078038T3 (da) * | 2006-10-13 | 2013-12-02 | Chiesi Farma Spa | Rekonstituerede surfaktanter med forbedrede egenskaber |
| EP1997502A1 (en) * | 2007-06-01 | 2008-12-03 | CHIESI FARMACEUTICI S.p.A. | Reconstituted surfactants having improved properties |
-
2010
- 2010-05-27 US US12/788,480 patent/US8399406B2/en active Active
- 2010-05-31 KR KR1020117028394A patent/KR101668137B1/ko active IP Right Grant
- 2010-05-31 CA CA2764454A patent/CA2764454C/en active Active
- 2010-05-31 CN CN201080024545.6A patent/CN102459327B/zh active Active
- 2010-05-31 DK DK10724708.2T patent/DK2438086T3/en active
- 2010-05-31 BR BRPI1010120-9A patent/BRPI1010120B1/pt active IP Right Grant
- 2010-05-31 LT LTEP10724708.2T patent/LT2438086T/lt unknown
- 2010-05-31 PT PT107247082T patent/PT2438086T/pt unknown
- 2010-05-31 MA MA34471A patent/MA33374B1/fr unknown
- 2010-05-31 GE GEAP201012486A patent/GEP20135967B/en unknown
- 2010-05-31 PL PL10724708T patent/PL2438086T3/pl unknown
- 2010-05-31 ME MEP-2011-197A patent/ME01279B/me unknown
- 2010-05-31 EA EA201190292A patent/EA021163B1/ru unknown
- 2010-05-31 SI SI201031433A patent/SI2438086T1/sl unknown
- 2010-05-31 UA UAA201114285A patent/UA103526C2/ru unknown
- 2010-05-31 AU AU2010256066A patent/AU2010256066B2/en active Active
- 2010-05-31 HU HUE10724708A patent/HUE034053T2/en unknown
- 2010-05-31 JP JP2012513503A patent/JP5666569B2/ja active Active
- 2010-05-31 EP EP10724708.2A patent/EP2438086B1/en active Active
- 2010-05-31 MX MX2011012951A patent/MX2011012951A/es active IP Right Grant
- 2010-05-31 SG SG2011089299A patent/SG176305A1/en unknown
- 2010-05-31 MY MYPI2011005866A patent/MY159464A/en unknown
- 2010-05-31 WO PCT/EP2010/003293 patent/WO2010139442A1/en active Application Filing
- 2010-05-31 NZ NZ596848A patent/NZ596848A/xx unknown
- 2010-05-31 PE PE2011002046A patent/PE20120541A1/es active IP Right Grant
- 2010-05-31 ES ES10724708.2T patent/ES2621974T3/es active Active
- 2010-06-03 TW TW099117884A patent/TWI457132B/zh active
- 2010-06-03 JO JOP/2010/0185A patent/JO3226B1/ar active
- 2010-06-03 AR ARP100101970A patent/AR076973A1/es not_active Application Discontinuation
-
2011
- 2011-11-04 TN TNP2011000558A patent/TN2011000558A1/en unknown
- 2011-11-25 CL CL2011003003A patent/CL2011003003A1/es unknown
- 2011-12-01 IL IL216718A patent/IL216718A/en active IP Right Grant
- 2011-12-02 CO CO11166483A patent/CO6470858A2/es active IP Right Grant
-
2012
- 2012-07-18 HK HK12107033.0A patent/HK1166332A1/xx unknown
-
2017
- 2017-02-24 CY CY20171100262T patent/CY1118676T1/el unknown
- 2017-03-21 HR HRP20170445TT patent/HRP20170445T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170445T1 (hr) | Poboljšani rekonstituirani pripravak surfaktanta koji sadrži analoge surfaktant-proteina b (sp-b) i surfaktant-proteina c (sp-c) | |
| KR101516443B1 (ko) | 개선된 특성을 가지는 재구성된 계면활성제 | |
| JP5108515B2 (ja) | 肺サーファクタント及びｔｎｆ由来ペプチドを含有する組成物 | |
| HRP20140052T1 (hr) | Rekonstituirani surfakanti koji imaju poboljšana svojstva | |
| JP2012515221A5 (hr) | ||
| US11951158B2 (en) | Compositions and methods for administering PPARγ agonists, surfactant peptides and phospholipids | |
| CA2891933C (en) | Recombinant pulmonary surfactants comprising sp-b and sp-c analogues and a phospholipid mixture | |
| ES2253003T3 (es) | Equipo de tratamiento que contiene composiciones a base de agentes tensioactivos pulmonares. | |
| CA2372558A1 (en) | Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c) | |
| KR102395835B1 (ko) | 재구성된 폐 계면활성제 조성물을 포함하는 안정한 약제학적 제제 | |
| KR20230019089A (ko) | 바이러스 감염을 치료하기 위한 계면활성제 단백질 d의 용도 | |
| US7638493B2 (en) | Artificial pulmonary surfactant compositions and use of the same |